title: Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?
authors.affiliation: a Mellen Center for Multiple Sclerosis Treatment and Research , Neurological Institute, Cleveland Clinic , Cleveland , OH , USA.
authors.forename: Ian T
authors.initials: IT
authors.lastname: Rossman
authors.affiliation: a Mellen Center for Multiple Sclerosis Treatment and Research , Neurological Institute, Cleveland Clinic , Cleveland , OH , USA.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Cohen
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000592:standards; D009103:Multiple Sclerosis / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D016896:Treatment Outcome